Epigenetic changes in cancer as potential targets for prophylaxis and maintenance therapy

Basic and Clinical Pharmacology and Toxicology

Volumn 103, Issue 5, 2008, Pages 389-396

  Grønbæk, Kirsten ^a   Treppendahl, Marianne ^a   Asmar, Fazila ^a   Guldberg, Per ^b  

^a Rigshospitalet   (Denmark)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 5 AZA 2' DEOXYCYTIDINE; 5 AZACYTIDINE PHOSPHATE GUANOSINE; ADENOSYLHOMOCYSTEINASE INHIBITOR; AZACITIDINE; BELINOSTAT; BUTYRIC ACID; DEAZANE PLANOCIN A; DNA; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; DZNEP; HISTONE; HISTONE DEACETYLASE INHIBITOR; MG 98; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; NICOTINAMIDE; PANOBINOSTAT; POLYAMINE DERIVATIVE; RG 108; ROMIDEPSIN; S 110; SIRTUIN; SPLITOMICIN; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; ZEBULARINE;

CANCER CHEMOTHERAPY; CANCER PREVENTION; CELL DIFFERENTIATION; COMBINATION CHEMOTHERAPY; CUTANEOUS T CELL LYMPHOMA; DNA METHYLATION; DRUG MECHANISM; DRUG TARGETING; EPIGENETICS; GENE INACTIVATION; HUMAN; MAINTENANCE THERAPY; MONOTHERAPY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NEOPLASM; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; SHORT SURVEY; SOLID TUMOR; T CELL LYMPHOMA; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DNA METHYLATION; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HISTONES; HUMANS; NEOPLASMS; TRANSCRIPTION, GENETIC;

EID: 53949084470     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2008.00325.x     Document Type: Short Survey

References (62)

1. Chiang PK, Gordon RK, Tal J, Zeng GC, Doctor BP, Pardhasaradhi K et al. S-Adenosylmethionine and methylation. FASEB J 1996 10 : 471 80.
2. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999 99 : 247 57.
3. Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci USA 2002 99 : 3740 5.
4. Rideout WM III, Coetzee GA, Olumi AF, Jones PA. 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science 1990 249 : 1288 90.
5. Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 2007 447 : 425 32.
6. Nan X, Campoy FJ, Bird A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 1997 88 : 471 81.
7. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998 19 : 187 91.
8. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002 3 : 415 28.
9. Lachner M, O'Carroll D, Rea S, Mechtler K, Jenuwein T. Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature 2001 410 : 116 20.
10. Santos-Rosa H, Schneider R, Bannister AJ, Sherriff J, Bernstein BE, Emre NC et al. Active genes are tri-methylated at K4 of histone H3. Nature 2002 419 : 407 11.
11. Margueron R, Trojer P, Reinberg D. The key to development: interpreting the histone code? Curr Opin Genet Dev 2005 15 : 163 76.
12. Cloos PA, Christensen J, Agger K, Helin K. Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease. Genes Dev 2008 22 : 1115 40.
13. Jenuwein T. The epigenetic magic of histone lysine methylation. FEBS J 2006 273 : 3121 35.
14. Shi Y. Histone lysine demethylases: emerging roles in development, physiology and disease. Nat Rev Genet 2007 8 : 829 33.
15. Lund AH, van LM. Polycomb complexes and silencing mechanisms. Curr Opin Cell Biol 2004 16 : 239 46.
16. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 2006 24 : 268 73.
17. Yu J, Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 2007 67 : 10657 63.
18. Kienle D, Katzenberger T, Ott G, Saupe D, Benner A, Kohlhammer H et al. Quantitative gene expression deregulation in mantle-cell lymphoma: correlation with clinical and biologic factors. J Clin Oncol 2007 25 : 2770 7.
19. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C et al. Epigenetic stem cell signature in cancer. Nat Genet 2007 39 : 157 8.
20. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, Cope L et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 2007 39 : 237 42.
21. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007 39 : 232 6.
22. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C et al. The polycomb group protein EZH2 directly controls DNA methylation. Nature 2006 439 : 871 4.
23. McGarvey KM, Greene E, Fahrner JA, Jenuwein T, Baylin SB. DNA methylation and complete transcriptional silencing of cancer genes persist after depletion of EZH2. Cancer Res 2007 67 : 5097 102.
24. Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, Charo C et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 2008 40 : 741 50.
25. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980 20 : 85 93.
26. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004 429 : 457 63.
27. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the cancer and leukemia Group B. J Clin Oncol 2006 24 : 3895 903.
28. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Köhler G, Wijermans P et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. Blood 2002 100 : 2957 64.
29. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004 103 : 1635 40.
30. Wijermans PW, Lubbert M, Verhoef G, Klimek V, Bosly A. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients. Ann Hematol 2005 84 : 9 17.
31. Fenaux P, Mufti GJ, Santini V, Finelli C, Giagounidis A, Schoch R et al. Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR): results of the AZA-001 phase III study. ASH Annual Meeting Abstracts 2007 110 : 817.
32. Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh LS, Lee SL et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 2005 11 : 3604 8.
33. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006 5 : 769 84.
34. Longo VD, Kennedy BK. Sirtuins in aging and age-related disease. Cell 2006 126 : 257 68.
35. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006 6 : 38 51.
36. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007 109 : 31 9.
37. Zelent A, Petrie K, Lotan R, Waxman S, Gore SD. Clinical translation of epigenetics in cancer: eN-CORe - a report on the second workshop. Mol Cancer Ther 2005 4 : 1810 9.
38. Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006 66 : 6361 9.
39. Pruitt K, Zinn RL, Ohm JE, McGarvey KM, Kang SH, Watkins DN et al. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet 2006 2 : e40.
40. Qiu J, Huang Y, Chen G, Chen Z, Tweardy DJ, Dong S. Aberrant chromatin remodeling by retinoic acid receptor alpha fusion proteins assessed at the single-cell level. Mol Biol Cell 2007 18 : 3941 51.
41. Cimino G, Lo-Coco F, Fenu S, Travaglini L, Finolezzi E, Mancini M et al. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res 2006 66 : 8903 11.
42. Grövdal M, Khan R, Aggerholm A, Antunovic P, Astermark J, Bernell P et al. Maintenance treatment with azacytidine for patients with high risk myelodysplastic syndromes or acute myeloid leukaemia in complete remission after intensive chemotherapy. ASH Annual Meeting Abstracts 2007 110 : 818.
43. Earel JK Jr., VanOosten RL, Griffith TS. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. Cancer Res 2006 66 : 499 507.
44. Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 2005 102 : 8567 72.
45. Sonnemann J, Kumar KS, Heesch S, Muller C, Hartwig C, Maass M et al. Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells. Int J Oncol 2006 28 : 755 66.
46. Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S et al. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res 2006 12 : 5869 78.
47. Yoo CB, Jeong S, Egger G, Liang G, Phiasivongsa P, Tang C et al. Delivery of 5-aza-2′-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res 2007 67 : 6400 8.
48. Cheng JC, Yoo CB, Weisenberger DJ, Chuang J, Wozniak C, Liang G et al. Preferential response of cancer cells to zebularine. Cancer Cell 2004 6 : 151 8.
49. Klecker RW, Cysyk RL, Collins JM. Zebularine metabolism by aldehyde oxidase in hepatic cytosol from humans, monkeys, dogs, rats, and mice: influence of sex and inhibitors. Bioorg Med Chem 2006 14 : 62 6.
50. Egger G, Aparicio AM, Escobar SG, Jones PA. Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2′- deoxycytidine treatment. Cancer Res 2007 67 : 346 53.
51. Brueckner B, Boy RG, Siedlecki P, Musch T, Kliem HC, Zielenkiewicz P et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res 2005 65 : 6305 11.
52. Winquist E, Knox J, Ayoub JP, Wood L, Wainman N, Reid GK et al. Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study. Invest New Drugs 2006 24 : 159 67.
53. Amato RJ. Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy. Clin Genitourin Cancer 2007 5 : 422 6.
54. Liang G, Gonzales FA, Jones PA, Orntoft TF, Thykjaer T. Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2′-deoxycytidine. Cancer Res 2002 62 : 961 6.
55. Hallas J, Friis S, Bjerrum L, Støvring H, Narverud SF, Heyerdahl T et al. Cancer risk in long-term users of Valproate: a population-based case-control study. APMIS 2008 116 : 440.
56. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL et al. Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007 21 : 1050 63.
57. Fiskus W, Pranpat M, Balasis M, Herger B, Rao R, Chinnaiyan A et al. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol Cancer Ther 2006 5 : 3096 104.
58. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004 119 : 941 53.
59. Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey JA, Richter M et al. p53 is regulated by the lysine demethylase LSD1. Nature 2007 449 : 105 8.
60. Huang Y, Greene E, Murray Stewart T, Goodwin AC, Baylin SB, Woster PM et al. Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc Natl Acad Sci USA 2007 104 : 8023 8.
61. Pasini D, Hansen KH, Christensen J, Agger K, Cloos PA, Helin K. Coordinated regulation of transcriptional repression by the RBP2 H3K4 demethylase and Polycomb-Repressive Complex 2. Genes Dev 2008 22 : 1345 55.
62. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer 2001 1 : 157 62.